Completed PHASE3 INTERVENTIONAL 2-arm NCT00848549

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

A Randomized, Double-Blind Extension Study To Assess The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Sponsor: Eisai Inc.

Conditions Epilepsy

Interventions Carbamazepine Zonisamide

Updated 6 times since 2017 Last updated: Dec 21, 2015 Started: Oct 31, 2008 Primary completion: Jun 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00848549, this PHASE3 trial focuses on Epilepsy and remains completed. Sponsored by Eisai Inc., it has been updated 6 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Inc.

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Alicante, Spain , Anyang, South Korea , Athens, Greece , Bangalore, India , Barcelona, Spain , Basel, Switzerland , Bedford Park, Australia , Belgrade, Serbia , Bellair, South Africa and 100 more locations